Short interest for Managed Portfolio Series Tremblant Global ETF gives investors a sense of the degree to which investors are betting on the decline of Managed Portfolio Series Tremblant Global ETF's stock. Short interest data is updated every two weeks.

Managed Portfolio Series Tremblant Global ETF (ARCA:TOGA), Short Interest Report

Managed Portfolio Series Tremblant Global ETF

Toga Ltd

Amneal's Q2 2024 injectable product launches:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Product launch</td>
<td colspan="1" rowspan="1">Dosage form</td>
<td colspan="1" rowspan="1">ASHP drug shortage</td>
</tr>
<tr>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">PEMRYDI RTU&#xAE;</td>
<td colspan="1" rowspan="1">Vial</td>
<td colspan="1" rowspan="1">No</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">Atropine sulfate</td>
<td colspan="1" rowspan="1">Prefilled syringe</td>
<td colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">Docetaxel</td>
<td colspan="1" rowspan="1">Injection</td>
<td colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td colspan="1" rowspan="1">4</td>
<td colspan="1" rowspan="1">Foscarnet</td>
<td colspan="1" rowspan="1">IV bag</td>
<td colspan="1" rowspan="1">No</td>
</tr>
<tr>
<td colspan="1" rowspan="1">5</td>
<td colspan="1" rowspan="1">Methylprednisolone acetate</td>
<td colspan="1" rowspan="1">Multi-dose vial</td>
<td colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td colspan="1" rowspan="1">6</td>
<td colspan="1" rowspan="1">Calcium gluconate</td>
<td colspan="1" rowspan="1">Vial</td>
<td colspan="1" rowspan="1">No</td>
</tr>
</tbody>
</table>
</figure>

Biotech

News

General

AMRX

Amneal Expands Broad Injectables Portfolio With The Addition of Six New Product Launches

WIIM

BYRN

Byrna Technologies shares are trading higher after the company announced preliminary Q2 revenues over $20 million.

B of A Securities analyst Brad Sills maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Underperform and raises the price target from $80 to $95.

Price Target

Analyst Ratings

GWRE

B of A Securities Maintains Underperform on Guidewire Software, Raises Price Target to $95

BTIG analyst Gray Powell maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and lowers the price target from $432 to $402.

CRWD

BTIG Maintains Buy on CrowdStrike Holdings, Lowers Price Target to $402

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $80 to $76.

MRUS

B of A Securities Maintains Buy on Merus, Lowers Price Target to $76

<ul>
<li>Interim CEO employment contract consists solely of equity compensation &nbsp;</li>
<li>Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement</li>
</ul>
BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President &amp; CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders.

Management

Insider Trades

AKTX

Akari Therapeutics Announces  Samir R. Patel, M.D., Has Assumed The Role Of Interim President & CEO, Increases Ownership To 14.2% With $1.25M Investment In Recent Private Placement

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $415 to $420.

Rosenblatt Maintains Buy on CrowdStrike Holdings, Raises Price Target to $420

SGRP

SPAR Group Enters Nn-Binding Letter Of Intent To Go Private With Highwire Capital; Highwire Has Offered To Acquire Co. For $2.50/Share

B of A Securities analyst Wamsi Mohan maintains Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) with a Neutral and raises the price target from $19 to $22.

B of A Securities Maintains Neutral on Hewlett Packard, Raises Price Target to $22

New enrollment locations offer convenient options for consumers to enroll or renew in TSA PreCheck
WASHINGTON and NEW YORK, June 5, 2024 /PRNewswire/ --&nbsp;CLEAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>), an authorized TSA PreCheck&#xAE; enrollment provider, continues to expand locations to enroll and renew consumers in the Trusted Traveler program by opening 7 new locations.
CLEAR now has 20 TSA PreCheck enrollment locations open across the U.S. The launch of the enrollment location at these 7 airports represents the ongoing expansion of CLEAR's national TSA PreCheck enrollment footprint. Throughout 2024, CLEAR will continue delivering convenience to consumers by launching additional locations and extended hours of operation for enrollment and renewals.
The 7 new locations include:
<ul>
<li>Washington Dulles International Airport (IAD)</li>
<li>San Francisco International Airport (SFO)</li>
<li>Minneapolis–Saint Paul International Airport (MSP)</li>
<li>Louis Armstrong New Orleans International Airport</li>
<li>William P. Hobby International Airport (HOU)</li>
<li>George Bush Intercontinental Airport (IAH)</li>
<li>Long Beach Airport (LGB)</li>
</ul>

CLEAR Expands Enrollment And Renewal Options By Opening 7 New Locations

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

MARA

Marathon Holdings Produced 616 Bitcoin In May, Increased BTC Holdings To 17,857 BTC

Preliminary Second Quarter Results Based on preliminary unaudited results, the Company expects total revenue for the fiscal second quarter of 2024 to be $20.3 million compared to $11.5 million in the fiscal second quarter of 2023. This 76% increase in revenue was seen across all consumer channels including Direct-to-Consumer (DTC), Amazon, Dealer, and Fox Labs. The Company attributes this surge in sales to the success of Byrna's new marketing strategies, including its celebrity endorsement campaign which it kicked off in Q4 of the previous year.
&nbsp;

Earnings

Guidance

Byrna Technologies Reports Preliminary Q2 2024 Revenue Of $20.3M Vs 17.74M Est

Waterdrop shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

B of A Securities analyst Jason Kupferberg maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Buy and lowers the price target from $419 to $365.

B of A Securities Maintains Buy on Accenture, Lowers Price Target to $365

The Nasdaq 100 closed higher by around 0.3% on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Snap</h3>
<ul>
<li>The Trade: Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) General Counsel Michael J. O&#8217;Sullivan <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 18,000 shares</a> at an average price of $15.01. The insider received around $270,241 from selling those shares.</li>
<li>What's Happening: Snap is investing in artificial intelligence and machine learning to enhance Snapchat, CEO Evan Spiegel recently said, aiming to make the app more engaging.</li>
<li>What Snap Does: Snap owns one of the most popular social networking apps, Snapchat, claiming more than 400 million daily active users as of the end of 2023.</li>
</ul>
Have a look at our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading">Levi Strauss</h3>
<ul>
<li>The Trade: Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) Director David A Friedman <a href="https://www.benzinga.com/sec/insider-trades/&quot;">sold a total of 16,666 shares</a> at an average price of $23.94. The insider received around $398,984 from selling those shares.</li>
<li>What's Happening: On April 11, Levi Strauss &amp; Co. named Gianluca Flore as Chief Commercial Officer.</li>
<li>What Levi Strauss Does: Levi Strauss &amp; Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi&#8217;s, Dockers, Signature by Levi Strauss &amp; Co. and Denizen brands</li>
</ul>
<h3 class="wp-block-heading">Owens &amp; Minor</h3>
<ul>
<li>The Trade: Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) EVP, CFO Alexander J Bruni <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 10,568 shares</a> at an average price of $17.76. The insider received around $187,688 from selling those shares.</li>
<li>What's Happening: On May 3, Owens &amp; Minor reported first-quarter adjusted EPS of 19 cents, up from 5 cents a year ago and beating the consensus of 18 cents.</li>
<li>What Owens &amp; Minor Does: Owens &amp; Minor Inc distributes consumable medical supplies to a variety of providers.</li>
</ul>
<h3 class="wp-block-heading">O&#8217;Reilly Automotive</h3>
<ul>
<li>The Trade: O&#8217;Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) Director Lawrence P Oreilly <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 3,000 shares</a> at an average price of $962.45. The insider received around $2.89 million from selling those shares.</li>
<li>What's Happening: On May 14, Evercore ISI Group analyst Greg Melich maintained O&#8217;Reilly Automotive with an Outperform and raised the price target from $1,255 to $1,275.</li>
<li>What O&#8217;Reilly Automotive Does: O&#8217;Reilly is an aftermarket automotive parts retailer in the United States and Mexico with nearly $16 billion in annual sales.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39157943/top-3-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 3 Tech And Telecom Stocks You May Want To Dump In June</a>

Short Ideas

Pre-Market Outlook

Trading Ideas

LEVI

ORLY

SNAP

Owens & Minor, O'Reilly Automotive And 2 Other Stocks Insiders Are Selling

BTIG analyst Matthew Vanvliet maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Buy and raises the price target from $135 to $140.

BTIG Maintains Buy on Guidewire Software, Raises Price Target to $140

TIGR

Up Fintech Holding shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

Every job seeker knows how finding a job can feel like full-time work in itself. The process requires constant attention to detail, endless rounds of stressful interviews, and facing the highs of potential opportunities and the lows of rejections.
Many recently defended a Gen Z job seeker, for rejecting a 90-minute task, after a CEO shared their interaction on X.com.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Me: really enjoyed the call. Please see attached financial modeling test Gen Z applicant: this looks like a lot of work. Without knowing where I stand in the process, I'm not comfortable spending 90 minutes in Excel Me:…well…I can tell you where you stand now
&mdash; m. stanfield (@mu2myoc) <a href="https://twitter.com/mu2myoc/status/1782755000105517241?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>A<a href="https://www.benzinga.com/money/overplay"> startup that turns videos into games gets backing from Mark Cuban</a> and opens a round for regular investors at $250.</li>
<li>A groundbreaking energy company plugs into the<a href="https://www.benzinga.com/money/dunamis-2"> $400 billion EV industry and is seeking investors</a>.</li>
</ul>
The CEO, known as M. Stanfield on the social media platform, informed Fortune that such tests are typical when hiring for an investment analyst position (the role the Gen Z applicant applied for), and the interview process was transparent.&nbsp;
They added, "One of the first things discussed in the interview is the steps in the process. I&#8217;m hiring an investment analyst. Underwriting potential real estate investments is the bulk of the job. No one was surprised when I sent the test."
Stanfield's follow-up tweet expressed that he would have appreciated a response: "I'm good at this and don&#8217;t work for free. Give me $1,000 and I'll break this deal down in amazing detail," adding, "Would have gladly paid and probably hired."
Trending: With returns as high as 300%, it&#8217;s no wonder this asset is the investment choice of many billionaires.<a href="https://www.benzinga.com/money/masterworks"> Uncover the secret</a>.
<h2 class="wp-block-heading">Why All The Backlash&nbsp;</h2>
While many criticized the job applicant, others argued that extensive pre-employment tests might exploit job seekers, extracting free labor without guaranteeing employment. This sentiment is echoed by many who have experienced similar scenarios. As one person tweeted, "To be fair, a lot of places are just using applicants for free labor. The job doesn&#8217;t exist. The &#8216;test&#8217; is the only work they need done."&nbsp;
Supporters of the job applicant point out that valuing one&#8217;s time and setting boundaries is not a negative trait. As another person added, "Because he values his time? The kid isn&#8217;t wrong just because we accepted this type of behavior from the Boomer employers our whole lives."
This incident&#8217;s backlash highlights a generational shift in attitudes toward work and the job application process. Gen Z, who have grown up in a digital age with access to abundant information and resources, often value efficiency and transparency. They are also more vocal about their expectations and boundaries, especially regarding unpaid work.
This incident&#8217;s discussion also delves into broader job market issues, including the fairness of recruitment practices and the power balance between employers and job seekers. While the CEO&#8217;s stance reflects a common practice in the investment industry, it raises questions about how these practices align with modern values and the evolving workplace landscape.
Ultimately, this serves as a reminder of the evolving job market, necessitating changes in the practices and expectations of employers and job seekers. As Gen Z continues to enter the workforce and <a href="https://www.benzinga.com/economics/macro-economic-events/24/05/39066076/are-boomers-crashing-the-economy-or-saving-it-why-investors-are-perplexed-and-wha">surpasses boomers</a> this year, their influence will undoubtedly shape the future of work, challenging traditional norms and advocating for a more equitable and respectful job application process.
Conversely, according to a Freedom Economy Index report, <a href="https://www.benzinga.com/personal-finance/24/03/37937158/survey-says-gen-z-workforce-is-toxic-least-reliable-and-thats-just-the-start">many employers have</a> labeled the Gen Z workforce as &#8216;toxic&#8217; and the &#8216;least reliable&#8217; among all generations. While 62% said that this generation was most likely to create toxicity and division at work, less than 4% of employers surveyed said Gen Z was the generation that aligned most with their culture.
These differing perspectives highlight significant generational differences. Bridging this huge gap will be important for a more harmonious workplace where neither generation looks at the other with discontent.&nbsp;
Keep Reading:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li>Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Investing in its booming real estate market has never been more accessible</a>.</li>
</ul>

Gen Z Job Applicant Rejects 90-Minute Task; CEO Faces Backlash

U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday.
Shares of DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) fell in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/24/06/39179786/douyus-q1-performance-falters-ceo-highlights-soft-market-challenges">first-quarter results.</a>
DouYu International reported a fiscal first-quarter 2024 revenue decline of 29.9% to $144 million year-on-year, missing the analyst consensus estimate of $184 million. The Chinese game-centric live streaming platform's adjusted earnings per ADS loss of 37 cents compared to $1.10 Y/Y, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
DouYu International shares fell 4.2% to $9.70 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares dipped 16.6% to $6.40 in pre-market trading.</li>
<li>Mind Medicine (MindMed) Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) shares declined 15.2% to $7.00 in pre-market trading after declining 5% on Tuesday.</li>
<li>Madrigal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) fell 12% to $215.00 in pre-market trading.</li>
<li>Annexon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares declined 11.5% to $5.30 in pre-market trading after the company announced a proposed public offering of common stock.</li>
<li>Integral Ad Science Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares fell 4.5% to $8.74 in pre-market trading.</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) shares fell 2.4% to $117.46 in pre-market trading after the company reported first-quarter earnings and announced a review of strategic alternatives for its Family Dollar business.</li>
<li>AMC Entertainment Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares declined 2.5% to $4.67 in pre-market trading.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/06/39176954/dollar-tree-hewlett-packard-enterprise-and-3-stocks-to-watch-heading-into-wednesday">Dollar Tree, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Wednesday</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Movers

ANNX

CMPS

DLTR

DOYU

MDGL

MNMD

DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<ul>
<li>New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral session &nbsp;</li>
<li>Preclinical data on ARQ-234, CD200R agonist, for the treatment of atopic dermatitis</li>
<li>Additional presentation of the consistent tolerability profile of topical roflumilast in psoriasis, seborrheic dermatitis, and atopic dermatitis &nbsp;</li>
</ul>
WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=luaRluioqgdFEuKYsbBe2vFu3MyvU4_UcCELMLOtZm1LGcDmplxO7e-Zr03J0kBdFSz2TiNWVkSBLYGK7ShL_p7rtTXLJOWzPtZzI5DETEs=">Arcutis Biotherapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, which will take place in Chicago, IL from June 8-10, 2024. Among these presentations will be new long-term safety and efficacy data for roflumilast cream 0.15% in patients ≥6 years of age with mild to moderate atopic dermatitis, and an encore of preclinical data on ARQ-234, a CD200 receptor agonist the Company is investigating for atopic dermatitis.
In addition, the Company will present investigator- and patient-rated local tolerability data evaluating topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.

ARQT

Arcutis Reports Multiple Abstracts, Including Oral Presentation At The Revolutionizing Alopecia Areata, Vitiligo, And Eczema Conference From June 8-10, 2024